Resources

Four of the most significant opportunities currently available to engage with global industry leaders

BIA CEO Chris Molloy discusses the vision for data report, rare disease R&D, Women in Biotech, Europe GMO rules, Bio€quity and Swiss Biotech Day

BioOrbit is enabling pharmaceutical drugs to be manufactured in space at scale

It has been an extremely challenging time for biotech post COVID-19 boom, but our Q1 financing report offers hope with continued positive momentum.

In this blog, Ethan Almond reflects on the inaugral BioSolutions UK conference, which brought together over 200 innovators, policymakers and industry leaders alongside an additional 29 investors.

The UK BioIndustry Association (BIA) is the UK’s trade association for innovative life sciences and the leading UK-wide forum for expert communities and high quality peer-to-peer networking in the sector.

In this blog, Ethan Almond reflects on the successes and innovative technology of biosolutions company and BIA member twig.

The UK’s biosolutions sector has established itself as a billion-pound frontier industry, with companies raising £1.46 billion in equity investment since 2018.

ELRIG announced the launch of Drug Discovery USA 2026.

Back from our Easter break, we’re hitting the ground running with an update on the publication of agreed text underpinning the UK-US pharmaceuticals agreement.

In this guest blog, Paul Jeffrey, Director of the GFIL/Cranfield Technology Accelerator at Cranfield Water Science Institute, explains how engineering biology solutions for environmental applications face unclear and complex regulatory pathways.

In this blog, Linda Bedenik, our Head of Biosolutions and International Policy, and Maddie Cass, our Policy and Public Affairs Manager, reflect on the tireless work they have done, and will continue to do, to propel innovative biosolutions in the UK nationally and across Europe.

In this blog, Jaime Eaton, reflects on this month's Community Connects series, bringing together diverse expertise to tackle the most pressing challenges in our sector.

RxCelerate launched RxPlorer™: a new technology for finding small molecule hits, particularly against challenging, previously undruggable targets.

Abselion has appointed Dale Gordon as Chair of the Board of Directors.

Salvivo has been awarded £99,080 in Innovate UK Analysis for Innovators funding to enable evaluation of its FishburneTabs™ platform for biomarker detection with the National Physical Laboratory (NPL).

Abselion, a pioneering life sciences technology company focused on simplifying biomolecule quantification, today announced that it has established a US subsidiary at The Engine in Cambridge, MA.

Harness Therapeutics nominates HRN001 as its lead drug candidate for Huntington's disease and the formation of a clinical advisory board to support advancement towards clinical evaluation.

ARC has launched Motherlabs Oxford, a new purpose-built life sciences accelerator space at its ARC Oxford campus, expanding its early-stage laboratory offering in response to sustained demand across the sector.